“About
Vivaldi”
With operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado and in Vienna, Austria, Vivaldi Biosciences is developing Delta NS1 vaccines for protection against epidemic and pandemic viral respiratory diseases. NGN Capital LLC is the company’s lead investor.
Management & Board of Directors
William Wick, MBA
CEO, Board Member and
Managing Director
CEO, Vivaldi Biosciences Inc.
Board Member, Vivaldi Biosciences Inc.
Managing Director, Vivaldi Biosciences AG
Investment, finance and operating professional with extensive C-level leadership experience in venture-backed medical and high-tech companies
• Lumendi LLC
• Vision Capital LLC
• ZoZa.com
• QuickPower, Inc.
• National City Corporation
Thomas Muster, PhD
CSO, Board Member and
Managing Director
CSO, Vivaldi Biosciences Inc.
Board Member, Vivaldi Biosciences Inc.
Managing Director, Vivaldi Biosciences AG
Virologist and entrepreneur, expert in clinical development of novel vaccines, co-authored more than 50 publications, holds 30 patents
• Blue Sky Vaccines
• AVIR Green Hills Biotechnology
• Mount Sinai School of Medicine
Manfred Reiter, PhD
Senior Vice President,
Manufacturing
Senior Vice President,
Manufacturing.
Leader in process development and manufacturing for human vaccines, expert in cell-based production and scale-up
• Blue Sky Vaccines
• Hookipa Biotech
• Baxter Bioscience
• Immuno AG
Amy Aspelund
Vice President,
Research & Development
Vice President,
Research & Development
Expert leadership in gene cloning and sequencing, vaccine strain development and optimization, and assay development
• MedImmune
• University of California, San Francisco
• Colorado State University
• Onyx Pharmaceuticals
Carrie Brown, MSc
Vice President,
Marketing & Communications
Vice President,
Marketing & Communications
Heads corporate and investor communications, strategic planning, market intelligence, and media relations
• Progenitor, Inc.
• Genetic Engineering News
• Battelle Memorial Institute
• Gibco / Life Technologies
Douglass Given, MD, PhD, MBA
Chairman
Chairman, Vivaldi Biosciences Inc.
Member, Supervisory Board, Vivaldi Biosciences AG
Managing Partner, Health 2047
Entrepreneur and venture capitalist with extensive pharma and biotech executive and board experience, physician
• Bay City Capital LLC
• Mallinckrodt
• Lilly
• Schering Plough
John Costantino, JD
Director
Director,Vivaldi Biosciences Inc.
Director, Supervisory Board, Vivaldi Biosciences AG
Managing General Partner, NGN Capital LLC
Expert in private equity, venture investing, and investment banking, C-level corporate experience, attorney, CPA
• Walden Partners
• Conair Corporation
• Integrated Resources Acquisition Corporation
• Touche Ross & Co.
Peter Johann, PhD
Director
Director, Vivaldi Biosciences Inc.
Member, Supervisory Board, Vivaldi Biosciences AG
Managing General Partner, NGN Capital LLC
Venture investor with extensive pharma industry experience including strategic planning, corporate development, M&A, marketing and licensing
• Boehringer Ingelheim
• Hoffmann-La Roche
• Boehringer Mannheim
Scientific Advisors
Peter Palese, PhD
Founder & Scientific Advisor
Founder & Scientific Advisor, Vivaldi Biosciences Inc.
Professor & Chair, Microbiology,
Professor, Medicine, Infectious Diseases,
Icahn School of Medicine at Mount Sinai
International leader in the study of viruses that cause respiratory diseases, influenza genomics, vaccines and antivirals, authored over 400 papers, holds multiple patents on vaccines and antivirals
• Member, National Academy of Sciences
• Member, Institute of Medicine
• Member, Austrian Academy of Sciences
• Member, German Academy of Sciences Leopoldina
• Member, American Academy of Arts and Sciences
Adolfo García-Sastre, PhD
Founder & Scientific Advisor
Founder & Scientific Advisor, Vivaldi Biosciences Inc.
Professor, Microbiology and Medicine; Director, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Expert in molecular biology of influenza and other negative strand RNA viruses, identified role of influenza NS1, co-developed reverse genetics techniques and live attenuated influenza viruses with modifications of NS1, authored over 480 papers and reviews
• Member, National Academy of Sciences
• Fellow, American Academy of Microbiology
• Fellow, Royal Academy of Pharmacy, Spain
Elliott Kieff, MD, PhD (1943-2024)
Founder & Scientific Advisor
Founder & Scientific Advisor, Vivaldi Biosciences Inc.
Professor of Medicine, Emeritus, Harvard Medical School
Senior Physician, Brigham & Women’s Hospital
Expert in virology and medicine, led discoveries in genetics and molecular pathogenesis of Epstein-Barr virus infection resulting in development of vaccines and immunotherapeutics, authored more than 230 papers, holds 11 patents
• Member, National Academy of Sciences
• Member, Institute of Medicine
• Member, American Academy of Arts and Sciences